You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 205271 - 205280 of 207712 results
  1. A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome

    SBC: NANOMETICS LLC            Topic: 102

    Problem to be SolvedCapecitabine is a widely prescribed and orally available prodrug of the chemotherapeutic agentfluorouracilFUThe principle dose schedule limiting toxicity associated with its use is Hand Foot syndromeHFSand occurs inof patients receiving capecitabineHFS manifests in the hands and feet of patientsand rapidly progresses to painful peelingblisteringand bleeding that commonly requir ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Ceraxa (Ceramide NanoLiposome) and Vinblastine For the Improved Treatment of Relapsed or Refractory Acute Myeloid Leukemia

    SBC: KEYSTONE NANO, INC.            Topic: 102

    ABSTRACT: This grant supports the clinical study of Keystone Nano’s (KN) Ceraxa (C6 Ceramide NanoLiposome) and Vinblastine (VBL) in patients with relapsed/refractory Acute Myeloid Leukemia (AML) at leading NCI cancer centers. A recently completed NCI-supported Phase 1 study in solid tumor patients (NCT 02834611) has shown no Dose Limiting Toxicities and only modest adverse events with Ceraxa at ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP

    SBC: PHARMAIN CORPORATION            Topic: NHLBI

    ABSTRACTThis application is seeking funding specifically for ChemistryManufacturingand ControlCMCof scale up production of long acting atrial natriuretic peptidedANPand its protected graft co polymerPGCexcipient for use in heart failureHFtreatmentThe extrinsic merit of this project will be the availability of cGMP grade PGC for use in prolonging the half life of various peptide drugs that are in p ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Precision Fiber Optic Gyroscope

    SBC: Los Gatos Research            Topic: MDA07052

    Gyroscopes are found in nearly every airplane, many cars, robots, missiles, and more. The reason for such broad, wide-spread use is simple: gyroscopes are excellent tools for determining rotation, and can be quite sensitive. Fiber-optic gyroscopes, though light weight and robust, have not been able to match the performance of ring-laser gyroscopes. To provide a solution, Los Gatos Research has ...

    SBIR Phase II 2009 Department of DefenseMissile Defense Agency
  5. The Advanced Climate Analysis and Forecasting System- Decision Support System

    SBC: CLEAR SCIENCE INC            Topic: N142121

    We propose 16 objectives based specific requirements requested by key stakeholders. These objectives reflect the increased use of the ACAF’s current capabilities coupled with a growing appreciation of the power of the emerging ACAF-DSS as a planning and research tool. With a functioning Phase II prototype context, we feel our technical objectives for Subsequent Phase II can be specific and focus ...

    SBIR Phase II 2020 Department of DefenseNavy
  6. Development of a POC device to guide efficient use of blood products

    SBC: HEMOSONICS            Topic: NHLBI

    DESCRIPTION provided by applicant The Problem The inability of blood to coagulate properly represents a major source of preventable morbidity mortality and unnecessary costs For example over of the patients undergoing cardio pulmonary bypass CPB procedures in the US each year experience excessive bleeding which requires transfusions of blood products There are four treatme ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Solid-state, Sub-nanosecond Pulse Sharpener for Generating High Power Impulses

    SBC: Transient Plasma Systems, Inc.            Topic: N201074

    In the Phase I Base effort of this program Transient Plasma Systems, Inc. (TPS) investigated the development of a solid-state electrical closing switch that is capable of producing high power electrical impulses with rising edges that are faster than 200 ps.  TPS subcontracted with GE Research to perform MIXED-MODE technology computer-aided design (TCAD) simulations to investigate the capability ...

    SBIR Phase II 2021 Department of DefenseNavy
  8. Robust Representation: Real-time Characterization of Streaming Data

    SBC: DZYNE TECHNOLOGIES, LLC            Topic: SB132002

    The volume and velocity of digital data collected and used for analysis is growing at an increasing rate and will soon exceed our ability to store and analyze it in a timely fashion.Additionally, much of these data represent changes in behaviors of the underlying networks and entities that they measure such that the rate of development of new analytics to keep up with events and trends, such as ch ...

    SBIR Phase II 2015 Department of DefenseDefense Advanced Research Projects Agency
  9. IGF OT IGF I CLR AS A NEO ADJUVANT TREATMENT OPTION FOR TRIPLE NEGATIVE BREAST CANCER PERIOD OF PERFORMANCE

    SBC: Cellectar Biosciences, Inc.            Topic: NCI

    Poor prognosis of triple negative breast cancer TNBC is attributable to the absence of efficacious molecularly targeted neoadjuvant therapies Micrometastases contribute to poor prognosis by increasing recurrence rate Consequently an effective treatment option that is capable of targeting and sterilizing micrometastatic disease in patients with TNBC is warranted I CLR is proposed as ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. MOONSHOT- TOPIC 372- DEVELOPMENT AND VALIDATION OF NON-MOUSE REAGENTS TO ENABLE PRECLINICAL DEVELOPMENT OF NOVEL THERAPEUTICS.

    SBC: Vetigenics LLC            Topic: 372

    As described in NIH/NCI Topic No. 372, the preclinical development of cancer therapeutics, including the recent trend and focus on cancer immunotherapies, is evolving from the traditional use of mouse models to the use of other animal models including canine, rat, and minipig. Of particular interest are reagents to be used in canine models of spontaneously occurring cancer that would facilitate th ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government